Many patients with schizophrenia or recurrent psychotic disorders want to reduce or stop their antipsychotic drugs to minimize adverse effects like sedation, weight gain, and emotional blunting, all of which can impair social functioning.

Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.